Benitec Biopharma (BNTC)
(Delayed Data from NSDQ)
$8.15 USD
-0.01 (-0.12%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $8.13 -0.02 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BNTC 8.15 -0.01(-0.12%)
Will BNTC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BNTC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for BNTC
Benitec Biopharma initiated with bullish view at Guggenheim
Benitec Biopharma Shareholders Approve Key Proposals
Franklin Biotechnology Discovery Fund Q2 2024 Commentary
Buy Rating on Benitec Biopharma: Anticipating BB-301’s Impact on OPMD Treatment and Stock Value
Benitec Biopharma initiated with bullish view at Leerink, here's why